COVID-19 中的 I 型干扰素反应：治疗意义。
The type I interferon response in COVID-19: implications for treatment.
机构信息
Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
GENOME INSIGHT Inc., Daejeon, Republic of Korea.
出版信息
Nat Rev Immunol. 2020 Oct;20(10):585-586. doi: 10.1038/s41577-020-00429-3.
Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19.
尽管早期有相反的报告，但越来越多的证据表明，严重 COVID-19 患者具有强烈的 I 型干扰素反应，这与感染早期出现的延迟、可能受抑制的干扰素反应形成对比。强烈的 I 型干扰素反应可能通过多种机制加剧向严重 COVID-19 的进展中的过度炎症。进一步了解 I 型干扰素在感染不同阶段以及轻度和重度 COVID-19 患者中的作用，将为 COVID-19 患者使用干扰素给药或 JAK 抑制剂的治疗提供依据。
Zotero 插件